Boston Scientific Corporation
BSX
Classement en actions
#409
Cette description de l'entreprise n'est disponible qu'en anglais.
Boston Scientific Corporation (BSX) operates as a global leader in medical... Boston Scientific Corporation (BSX) operates as a global leader in medical technology, specializing in the design, manufacturing, and commercialization of innovative medical devices tailored for a diverse array of interventional medical specialties across the globe. Its business is strategically organized into three principal segments: MedSurg, Rhythm and Neuro, and Cardiovascular. Within these divisions, the company provides a comprehensive portfolio of solutions addressing various gastrointestinal and pulmonary ailments, as well as urological and pelvic health concerns. This extends to advanced implantable devices for managing cardiac rhythm disorders, such as cardioverter-defibrillators, cardiac resynchronization therapy devices, and pacemakers, complemented by remote patient management systems. Furthermore, Boston Scientific offers sophisticated technologies for diagnosing and treating complex heart rate and rhythm irregularities. These encompass 3-D cardiac mapping and navigation tools, along with a suite of specialized catheters (including ablation, diagnostic, mapping, and intracardiac ultrasound types), delivery sheaths, and related accessories. Its offerings also extend to neurological conditions, providing spinal cord stimulator systems for chronic pain management, indirect decompression systems, and deep brain stimulation systems. In the realm of interventional cardiology, the company's innovations include drug-eluting coronary stent systems designed for treating coronary artery disease, products for percutaneous coronary interventions to combat atherosclerosis, and intravascular imaging catheters (such as ultrasound and fractional flow reserve devices) for assessing coronary arteries, heart chambers, and peripheral vessels. It also develops structural heart therapies. Beyond this, Boston Scientific supplies an array of stents, balloon catheters, wires, and atherectomy systems for the treatment of arterial diseases. For venous conditions, it provides thrombectomy and acoustic pulse thrombolysis systems, alongside wires and stents. Critically, the company also contributes to cancer treatment through peripheral embolization devices, radioactive microspheres, various ablation systems (including cryotherapy), and micro and drainage catheters. The organization was established in 1979 and maintains its corporate headquarters in Marlborough, Massachusetts.
Prix de l'action
$41.88
Dernière synchronisation: 2026-10-30
Capitalisation boursière
$60.69B
Variation (1 jour)
-1.89%
Variation (1 an)
-58.42%
Pays
US
Données boursières : Financial Modeling Prep·Mis à jour le ·Ceci n'est pas un conseil en investissement·Comment nous calculons
Échange Boston Scientific Corporation (BSX)
Catégorie
Healthcare
Bénéfices pour Boston Scientific Corporation (BSX)
Bénéfices en Sep 2026 TTM : $3.66B
Selon les derniers rapports financiers de Boston Scientific Corporation, les bénéfices actuels de l'entreprise sont de $3.66B. En 2025, l'entreprise a réalisé un bénéfice de $3.39B, une augmentation par rapport à celui de 2024 qui était de $2.28B. Les bénéfices affichés sur cette page correspondent aux bénéfices avant intérêts et impôts, appelés aussi EBIT.
Historique des bénéfices pour Boston Scientific Corporation de 2000 à 2026
Bénéfices à la fin de chaque année
| Année | Bénéfices | Variation |
|---|---|---|
| 2026 (TTM) | $3.66B | 7.98% |
| 2025 | $3.39B | 48.33% |
| 2024 | $2.28B | 14.96% |
| 2023 | $1.99B | 73.97% |
| 2022 | $1.14B | 6.04% |
| 2021 | $1.08B | -1,462.03% |
| 2020 | $-79.00M | -111.50% |
| 2019 | $687.00M | -51.69% |
| 2018 | $1.42B | 52.41% |
| 2017 | $933.00M | 427.12% |
| 2016 | $177.00M | -127.23% |
| 2015 | $-650.00M | 27.70% |
| 2014 | $-509.00M | 128.25% |
| 2013 | $-223.00M | -94.57% |
| 2012 | $-4.11B | -739.72% |
| 2011 | $642.00M | -160.40% |
| 2010 | $-1.06B | -18.73% |
| 2009 | $-1.31B | -35.60% |
| 2008 | $-2.03B | 256.94% |
| 2007 | $-569.00M | -83.90% |
| 2006 | $-3.54B | -496.75% |
| 2005 | $891.00M | -40.36% |
| 2004 | $1.49B | 132.35% |
| 2003 | $643.00M | 17.12% |
| 2002 | $549.00M | 1,147.73% |
| 2001 | $44.00M | -91.65% |
| 2000 | $527.00M | 0.00% |
Bénéfices des entreprises similaires ou concurrentes
| Entreprise | Bénéfices | Différence de bénéfices | Pays |
|---|---|---|---|
| $6.56B | 79.53% |
US
|
|
| $6.60B | 80.66% |
IE
|
|
| $5.12B | 39.97% |
US
|
|
| $3.23B | -11.70% |
DE
|
|
| $1.42B | -61.21% |
US
|
Questions sur le bénéfice net de Boston Scientific Corporation
À combien s'élève le bénéfice net de Boston Scientific Corporation ?
Selon les dernières données (sept. 2026), le bénéfice net de Boston Scientific Corporation sur les douze derniers mois s'élève à $3.66B.
À combien s'élevait le bénéfice net de Boston Scientific Corporation en 2025 ?
En 2025, le bénéfice net de Boston Scientific Corporation s'élevait à $3.39B, soit 48.33% de plus qu'en 2024 ($2.28B).
Comment a évolué le bénéfice net de Boston Scientific Corporation depuis 2020 ?
De 2020 à 2025, le bénéfice net de Boston Scientific Corporation a atteint son plus haut niveau en 2025 ($3.39B) et son plus bas niveau en 2020 ($-79.00M).
Comment se situe le bénéfice net de Boston Scientific Corporation par rapport aux entreprises similaires ?
Avec $3.66B, le bénéfice net de Boston Scientific Corporation dépasse la valeur de 2 des 5 entreprises similaires présentées ci-dessus. Parmi elles, la valeur la plus élevée est celle de Medtronic plc ($6.60B).